Patent Application
20220348624
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy is named GBSHJL008_Sequence Listing.txt, created on 03/14/2022 and is 107,999 bytes in size.
The present invention belongs to the field of molecular biology, and particularly relates to a recombinant interleukin-15 analog and expression thereof.
Interleukin-15 (IL-15) is a cytokine having a size of about 12 to 14 kD. The mature peptide of natural human interleukin-15 contains 114 amino acids, including 4 cysteine residues. Two pairs of intramolecular disulfide bonds respectively formed by the connection of Cys35 and Cys85 and the connection of Cys42 and Cys88 play an important role in maintaining the spatial conformation and biological activity of IL-15.
Similar to most cytokines, IL-15 plays a role in normal immune responses, such as promoting the development of T cells, B cells and natural killer (NK) cells. IL-15 and IL-2 share the same β chain and γ chain receptors, thus their biological activities are very similar. Due to the different a chain receptors, IL-2 can activate Treg cells and induce Teff and NK cell apoptosis (AICD), thus the clinical application of IL-2 is greatly limited. In contrast, IL-15 of the same family does not have the functions of Treg activation and AICD, thus IL-15 has great therapeutic potential.
The a subunit of the IL-15 receptor has a high affinity for IL-15. Under physiological conditions, IL-15 mostly forms a complex (IL-15-Ra) with the a subunit, which enhances the affinity of IL-15 for the β chain subunit and the γ chain subunit of the receptor, and activates T cells and NK cells. Thereby, companies such as ALTOR and Hengrui have utilized the characteristics of the a subunit to form a complex with IL-15 and a subunit (or its part) through fusion or non-fusion methods, which has shown good biological potency and stability in animal experiments.
The α subunit of IL-15 receptor is expressed on the surface of myeloid cells, including macrophages, antigen-presenting cells, NK cells and T cells. It also plays an important role in anti-tumor in vivo. Therefore, the IL-15-Ra complex is independent of the α subunit in vivo. Although the stability of IL-15 monomer is improved, it has a subtle functional difference from native IL-15, which may reveal essential differences in antitumor in vivo.
IL-15 has higher safety and activity as compared to IL-2. However, as a protein drug, natural wild-type IL-15 has significant drug development bottlenecks, including low expression levels in prokaryotes and eukaryotes, difficult purification, and short half-life, making it difficult to be industrialized. Therefore, it is necessary to study the exogenous expression of IL-15 to obtain high production efficiency. In addition, the N-terminal or C-terminal of IL-15 analog obtained by in vitro renaturation can be coupled to the fatty acid chain of human serum albumin binder, so as to achieve a long-term efficacy, which has certain significance for the treatment of tumors.
In view of the low production efficiency of IL-15 in the prior art, the present disclosure provides an IL-15 analog with high expression level and relatively simple purification process. Further, the present disclosure provides a conjugate of the IL-15 analog, thus as to improve the half-life of IL-15 and the long-term efficacy thereof.
In the first aspect, the present disclosure provides an IL-15 analog. In a particular embodiment, the amino acid sequence of the IL-15 analog comprises the amino acid sequence of IL-15, and one or more amino acids added to the C-terminal of the amino acid sequence of IL-15.
Preferably, the aforementioned one or more amino acids comprise positively charged amino acid.
Preferably, the amino acid sequence of the IL-15 analog is characterized by:
IL-15-Xa-Yb-Zc
wherein X, Y and Z each represent an amino acid sequence added at the C-terminal, and a, b and c each represent the number of the amino acids; and
wherein X and Z each are any amino acid or a combination of any amino acids, and a and c each are 0 to 20; and wherein Y is a positively charged amino acid or a combination of any positively charged amino acids, or a combination of a positively charged amino acid and any other amino acids, and b is 1 to 7.
Preferably, the positively charged amino acid is H, R or K.
Optionally, the aforementioned X comprises any one of V, I, P, L, E, A, S, C, T and G, or a combination thereof.
Optionally, the amino acid sequence of the IL-15 analog is characterized by:
IL-15-linker-Xa-Yb-Zc
wherein the linker represents a linker sequence between the amino acid sequence of IL-15 and the amino acid sequences added to the C-terminal thereof.
Preferably, the linker is (GGGGS)n (SEQ ID NO: 120), (GS)n or (GAPQ)n (SEQ ID NO: 121), with n being 0 to 10.
Preferably, Xa comprises LPBTG (SEQ ID NO: 151) with B being any amino acid, and the linker is (GS)n.
Optionally, the amino acid sequence added to the C-terminus of the IL-15 analog is selected from the group shown in Table 1.
Preferably, the amino acid sequence of IL-15 is selected from the group of:
1) the amino acid sequence shown in SEQ ID NO: 1;
2) an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 1 through substitution, deletion or addition of one or more amino acids; and
3) an amino acid being at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 1.
In the second aspect, the present disclosure provides a nucleotide sequence encoding the IL-15 analog as described above.
In the third aspect, the present disclosure provides a method for preparing an IL-15 analog, wherein the IL-15 analog as described above is expressed in a prokaryotic system.
Preferably, a nucleotide sequence encoding the IL-15 analog is linked to a prokaryotic expression vector, and transferred into prokaryotic expression host bacterium, which is induced to express the IL-15 analog.
Optionally, the IL-15 analog is expressed in the form of inclusion bodies, and the inclusion bodies are renatured.
Optionally, the inclusion bodies are dissolved in 8 M urea solution and purified by ion exchange and reverse phase chromatography.
Optionally, the prokaryotic expression vector is pET41a, and the expression host bacterium is Escherichia Coli BL21 (DE3) or C41 (DE3).
In the fourth aspect, the present disclosure provides a recombinant expression vector comprising a nucleotide sequence encoding the IL-15 analog as described above.
In the fifth aspect, the present disclosure provides a host bacterium transformed with a nucleotide sequence encoding the IL-15 analog as described above.
In the sixth aspect, the present disclosure provides a conjugate of the IL-15 analog, the amino acid sequence of the IL-15 analog comprises the amino acid sequence of IL-15, and one or more amino acids added to the C-terminal of the amino acid sequence of IL-15; and wherein the conjugate of the IL-15 analog is obtained by linking the IL-15 analog with a fatty acid chain.
Preferably, the amino acid sequence of the IL-15 analog is characterized by one of:
1) IL-15-Xa-Yb-Zc
wherein X, Y and Z each represent an amino acid sequence added at the C-terminal, and a, b and c each represent the number of the amino acids; and
wherein X and Z each are any amino acid or a combination of any amino acids, and a and c each are 0 to 20; and
wherein Y is a positively charged amino acid or a combination of any positively charged amino acids, or a combination of a positively charged amino acid and any other amino acids, and b is 1 to 7; and
2) IL-15-linker-Xa-Yb-Zc
wherein the linker represents a linker sequence between the amino acid sequence of IL-15 and the amino acid sequences added to the C-terminal thereof.
Preferably, Xa comprises LPBTG (SEQ ID NO: 151) with B being any amino acid, and the linker is (GS)n with n being 0 to 10.
Preferably, the fatty acid chain is —(CH2)m—COOH, wherein m is 12 to 19.
Preferably, the IL-15 analog and the fatty acid chain are linked by in vitro coupling.
Preferably, the in vitro coupling comprises:
1) coupling through enzymatic reaction, wherein the fatty acid chain in the enzymatic reaction has GGG at the N-terminal;
2) coupling with free cysteine residues introduced into the IL-15 analog; and
3) coupling with the amino group at the N-terminal of the IL-15 analog.
Preferably, when coupling through enzymatic reaction, the fatty acid chain has 3 glycine residues at the N-terminal; when coupling with free cysteine residues introduced into the IL-15 analog, the fatty acid chain has a maleimide ester or a halogenated reactive group; and when coupling with the amino group at the N-terminal of the IL-15 analog, the fatty acid chain has an aldehyde group or a succinimidyl ester functional group.
Optionally, the IL-15 analog is obtained by adding a sequence comprising -GS-LPETG (SEQ ID NO: 152) to the terminal of the amino acid sequence of IL-15.
Optionally, the fatty acid chain is selected from the group consisting of:
The present inventors have found that the expression of IL-15 in Escherichia Coli could be promoted by adding some amino acids to the C-terminal of IL-15, and that positively charged amino acids could significantly enhance the expression of IL-15. The present IL-15 analog is highly expressed in Escherichia Coli, and the expression level is about 20 or even more fold higher than that of IL-15 without extra amino acids at the C-terminal. All or most of the present IL-15 analog retains the amino acid sequence of the natural wild-type IL-15, and there is no significant difference in cell activity in vitro, which lays a foundation for the industrialization of IL-15 protein drugs.
In the present disclosure, a fatty acid chain is linked with the IL-15 analog through in vitro coupling to form a coupling product of IL-15 analog-fatty acid chain. Since the fatty acid chain is a ligand of albumin and can bind to albumin in blood, the IL-15 analog-fatty acid chain coupling product entering the body will form an IL-15 analog-fatty acid chain-albumin complex. On one hand, it can increase the molecular weight to escape from the renal filtration. On the other hand, hydrolysis by intracellular lysosomes can be avoided through the binding of albumin to FcRn which mediates recycling pathway as a protection mechanism, thereby achieving a long-acting mechanism of IL-15 analog-fatty acid chain coupling product. Herein, the conjugate of the present IL-15 analog is not in the form of a drug that is co-expressed with the IL-15 receptor a subunit to form a complex as used by most domestic and foreign companies. Instead, it retains the same cellular biological pattern as native IL-15, that is, it completely retains its binding to the IL15Rα receptor to participate in signal transduction and to function in vivo.
Hereinafter, the present invention will be further described in conjunction with examples. It should be understood that these examples are used for illustrative purposes only and are not intended to limit the protection scope of the present invention.
In the following examples, the experimental methods without special instructions were usually carried out in accordance with conventional conditions or in accordance with the conditions recommended by the manufacturer. See, for example, Sambrook et al, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). Unless otherwise specified, the reagents used are commercially available or publicly available reagents.
In particular embodiments according to the present disclosure, the positively charged amino acids were leucine (Lys, K), arginine (Arg, R) and histidine (His, H).
As the basis for modification, the amino acid sequence of IL-15 was selected from the group of:
1) the amino acid sequence shown in SEQ ID NO: 1;
2) an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 1 through substitution, deletion or addition of one or more amino acids; and
3) an amino acid being at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 1.
In particular embodiments according to the present disclosure, the expression of IL-15, especially in prokaryotic expression systems, could be enhanced by adding one or more amino acids, especially positively charged amino acids, to the C-terminal of IL-15.
In some particular embodiments, the amino acid sequence of the IL-15 analog could be represented as the following general formula (that is, the amino acid sequence Xa-Yb-Zc was added to the C-terminal of IL-15):
IL-15-Xa-Yb-Zc
wherein X, Y and Z each represented an amino acid sequence added at the C-terminal, and a, b and c each represented the number of the amino acids; and
wherein X and Z each were any amino acid or a combination of any amino acids, and a and c each were 0 to 20; and
wherein Y was a positively charged amino acid or a combination of any positively charged amino acids, or a combination of a positively charged amino acid and any other amino acids, and b was 1 to 7.
In some particular embodiments, the amino acid sequence of the IL-15 analog could be represented as the following general formula (that is, a linker sequence and the amino acid sequence Xa-Yb-Zc were added to the C-terminal of IL-15):
IL-15-linker-Xa-Yb-Zc
wherein X, Y and Z each represented an amino acid sequence added at the C-terminal, and a, b and c each represented the number of the amino acids; and
wherein X and Z each were any amino acid or a combination of any amino acids, and a and c each were 0 to 20; and
wherein Y was a positively charged amino acid or a combination of any positively charged amino acids, or a combination of a positively charged amino acid and any other amino acids, and b was 1 to 7.
In some optional particular embodiments, the linker could be (GGGGS)n, (GS)n or (GAPQ)n, with n being 1 to 5.
In some particular embodiments, in the above general formula of the amino acid sequence of IL-15 analogs, Xa comprised LPBTG (SEQ ID NO: 151), wherein B was any amino acid and the linker was (GS)n, with n being 0 to 10. In a particular embodiment, the IL-15 analog was obtained by adding a sequence comprising -GS-LPETG (SEQ ID NO: 152) to the terminal of the amino acid sequence of IL-15.
In some particular embodiments, the IL-15 analogs were coupled with fatty acid chains in vitro to improve the long-term efficacy of the IL-15 analogs. The way of in vitro coupling of fatty acid chains could be selected from the group of:
1) coupling with the amino group at the N-terminal, for example, through an aldehyde group or a succinimide ester;
2) site-directed coupling with the introduced free cysteine residue (for example, introducing a free cysteine residue at the C-terminal of the IL-15 analog), through a maleimide group or a halogenated group; and
3) utilizing an enzymatic reaction, for example, the enzyme Sortase A could utilize the small peptide LPETG (SEQ ID NO: 153) at the C-terminal of IL-15 to couple the IL-15 with the fatty acid chain with GGG at the N-terminal (see M. L. Bentley et al., J. Biol. Chem. 2008, 283: 14762-14771). The fatty acid chains could comprise the structure as shown in Table 2.
1.1 Construction of Expression Vector
The wild-type IL-15 nucleotide sequence was synthesized by Sangon Biotech (Shanghai).
(1) Design of Primers
The sequence of the C-terminal of IL-15 was altered by introducing a base sequence of different amino acids to be added into the reverse primer. The amino acid sequence, the nucleotide sequence and the primer sequence (used in the construction of IL-15 analogs) of the wild-type IL-15 and constructed IL-15 analogs are shown in Table 3.
The analogs 34 to 43 were formed by introducing mutations into the wild-type IL-15 to form IL-15 mutants, and then adding the sequence GSLPETGGGSGGSHHHHHH (SEQ ID NO: 220) to the C-terminals based on the IL-15 mutants. The analogs 34- to 43- were the mutants of IL-15 formed just after the mutations were introduced, without further adding the sequence GSLPETGGGSGGSHHHHHH (SEQ ID NO: 220) to the C-terminals. The nucleotide sequences of the mutated analogs 34 to 43 and analogs 38- to 43- without adding the sequence GSLPETGGGSGGSHHHHHH (SEQ ID NO: 220) to the C-terminals were synthesized by the Genewiz, Inc., and cloned into the pET41a vectors.
(2) PCR Amplification
The PCR amplification was classified into three cases as follows.
In the first case, only one reverse primer was required, and a total of 1 run of PCR was performed.
Sample loading system: 50 μL (1 tube)
Primers: forward primer and reverse primer
Template: IL-15
Annealing temperature: 61° C.
Extension time: 30 s
In the second case, two reverse primers were required, and a total of 2 runs of PCR were performed.
1st Run of PCR
Sample loading system: 20 μL (1 tube)
Primers: forward primer and reverse primer 1
Template: IL-15
Annealing temperature: 61° C.
Extension time: 30 s
2nd run of PCR
Sample loading system: 50 μL (1 tube)
Primers: forward primer and reverse primer 2
Template: PCR product of 1st run
Annealing temperature: 61° C.
Extension time: 30 s
In the third case, three reverse primers were required, and a total of 3 runs of PCR were performed.
1st run of PCR
Sample loading system: 20 μL (1 tube)
Primers: forward primer and reverse primer 1
Template: IL-15
Annealing temperature: 61° C.
Extension time: 30 s
2nd run of PCR
Sample loading system: 20 μL (1 tube)
Primers: forward primer and reverse primer 2
Template: PCR product of 1st run
Annealing temperature: 61° C.
Extension time: 30 s
3rd run of PCR
Sample loading system: 50 μL (1 tube)
Primers: forward primer and reverse primer 3
Template: PCR product of 2nd run
Annealing temperature: 61° C.
Extension time: 30 s
Sample Loading System for PCR: 20 μL
Sample Loading System for PCR: 50 μL
Amplification Procedure for PCR:
(3) Enzyme Digestion of Vector
Reaction system: 30 μL, incubating at 37° C. overnight after mixing
(4) PCR Products and Digested Vectors in the Gels were Recovered.
(5) Loading of Recombinants
Reaction system: 20 μL
The molar ratio of vector to fragment was 2:1. After reacting at 37° C. for 30 min, it was immediately cooled on ice and transformed into DH5α.
(6) Sterility Test
0.5 mL of Amp-resistant LB media was added to a 1.5 mL centrifuge tube and well-grown single colonies were inoculated thereto. A total of 5 tubes were inoculated and they were incubated in a shaker under shaking at 37° C. After incubation for 3 h, 1 μL of the culture was taken as a template for PCR of the bacterial suspension.
Reaction system for PCR: 10 μL
Amplification Procedure for PCR:
After PCR was completed, it was detected by agarose gel electrophoresis. Three positive clones were selected for sequencing (Sangon Biotech).
(7) Preservation of Positive Bacterial Suspension and Extraction of Plasmids
The positive clones with correct sequencing were inoculated into 5 mL of Amp-resistant LB liquid media with an inoculation volume of 10 μL. 500 μL of bacterial suspension was added into a 1.5 mL centrifuge tube. 500 μL of 40% glycerol was added for storage. It was labeled with the name, host bacteria and date, capped and stored in a refrigerator at −80° C.
The remaining bacterial suspension was collected by centrifugation for plasmid extraction.
1.2 Protein Expression of Wild-Type IL-15 and IL-15 Analogs
(1) Transformation of BL21 (DE3)
a) 2 μL of plasmid was added to 100 μL of BL21 (DE3) competent cells, and it was mixed immediately and placed on ice for 30 min.
b) It was heat-shocked at 42° C. for 90 s, followed by a rapid ice bath for 2 min.
c) 500 μL of LB media was added, then it was incubated at 37° C. under shaking (≤200 rpm) for 60 minutes.
d) It was centrifuged at 6000 rpm for 1 min. Most of the supernatant was discarded, and about 100 to 150 μL of the supernatant was retained. After the pellet was resuspended, they were spread on LB plates containing Amp and cultured at 37° C. overnight.
(2) Small-Scale Expression
a) Bacteria preservation: One single clone was picked into 1 mL of Amp-resistant LB media. It was incubated at 37° C. under shaking at 220 rpm for about 5 h. 1 mL of 40% glycerol was added. It was divided into 2 tubes and cryopreserved at −80° C.
b) 2.5 mL of LB liquid media containing Amp was added to the tube in the previous step. The culture was incubated at 37° C. under shaking at 220 rpm overnight.
c) The bacterial suspension incubated overnight was inoculated into 20 mL of LB media containing Amp at a ratio of 1:50. It was incubated at 37° C. under shaking at 220 rpm to reach OD600=0.6 (about 3 h). IPTG was added at a final concentration of 0.5 mM. It was incubated at 37° C. under shaking at 220 rpm for 3 h.
(3) Expression Level Determination by SDS-PAGE
a) The cultural suspension was determined for OD600. 10 OD bacterial suspension was taken, and centrifuged at 10000 rpm for 2 min. The supernatant was removed.
b) The pellet was resuspended with 1 mL of lysis buffer (10 mM Tris-HCl, pH 8.0) placed on ice and lysed by ultrasonication. Ultrasonic conditions: 130 W, 4 min, on 3 s, off 3 s.
c) After ultrasonication, 80 μL was taken and labeled as “T (total)”. The remaining liquid was centrifuged at 12000 rpm for 10 min to obtain “S (supernatant)” and “P (pellet)”. 20 μL of 5×Reducing Loading Buffer was added to 80 μL of T, P and S, respectively. Then they were heated at 95° C. for 5 min and 12.5 μL (0.1 OD) of each sample was taken for SDS-PAGE electrophoresis.
The electrophoretogram of wild-type IL-15 was shown in
(4) Expression Level Determination by HPLC
a) After expression, 10 OD cells were collected and resuspended with 1 mL of 10 mM Tris-HCl buffer at pH 8.0.
b) Sonication was performed under the same conditions as those for running gel electrophoresis as described in the above step (3).
c) After sonication, it was centrifuged at 12000 rpm for 10 min. The supernatant was discarded.
d) The pellet was added with 1 mL of freshly prepared 8 M Urea/10 mM Tris-HCl (pH 8.0, 10 mM DTT) and dissolved by shaking at room temperature for about 1 h.
e) It was filtered with a 0.2 μm filter and loaded for HPLC analysis. The analysis was performed using a C4 analytical column with 0.1% TFA in deionized water as mobile phase A and 0.1% TFA in acetonitrile as mobile phase B, followed by a 15-minute gradient from 20% B to 60% B.
As shown by the HPLC quantitative results in
2.1 Preparation of IL-15 Analogs
The IL-15 analogs 11, 18, 21 and 28 expressed by the inclusion bodies were dissolved in 8 M urea solution, and purified by ion exchange and reversed-phase chromatography (for details, see: Yunier Rodriguez-Alvarez et al, Preparative Biochemistry and Biotechnology, 47: 9, 889-900), to obtain relatively pure proteins. The SDS-PAGE electrophoretograms were shown in
2.2 CTLL-2 Cell Proliferation Assay
The CTLL-2 cell proliferation assay is commonly used to detect the activity of immune cells stimulated by interleukin at the cellular level. Therefore, the biological activity of IL-15 analogs was determined herein by the proliferative effect of the wild-type IL-15 and IL-15 analogs on CTLL-2 cells.
1) Preparation of CTLL-2 Cells: The Cells were Resuspended in Media Containing FBS and Rat-T-Stim.
2) Loading: the cells were seeded in a 96-well culture plate at 0.1 mL per well. At the same time, the proteins samples of IL-15 analogs 11, 18, 21 and 28 to be tested (i.e., the proteins prepared in step 2.1) were diluted by multiples, respectively. 0.1 mL was added to each well, and 3 replicate wells were set for each dilution concentration. The control well for culture media was set (100 μL cells+100 μL culture media). The plate was incubated at 37° C. with 5% CO2 for 72 hours.
3) MTS addition: 20 μL of CellTiter96® AQueous One Solution Reagent was added to each well, and the plate was incubated at 37° C. with 5% CO2 for 2 to 4 hours.
4) Detection: the absorbance value (A) was measured at a wavelength of 490 nm with a microplate reader and the EC50 value was calculated.
The results were shown in Table 5. There was no significant difference in the cellular activity of the IL-15 analogs and wild-type IL-15.
The purified IL-15 Analog 21 (IL-15-GS-LPETG-GSGGSHHHHHH) was used in this example. The fatty acid chain (816366) with GGG at the N-terminal was linked to IL-15-GS-LPETG-GSGGSHHHHHH by a ligation reaction catalyzed by the transpeptidase Sortase A. The reaction was carried out in a Sortase A: IL-15: fatty acid chain ratio of 1:6:30, wherein the reaction buffer was 50 mM Tris-HCl (1 mM CaCl, 150 mM NaCl, pH 8.0). After reacting at room temperature for 3 hours, purification was carried out. Reversed-phase chromatography C8 (Sepax Technologies, Inc.) was used for purification to separate the unconjugated IL-15 Analog 21 and the unreacted fatty acid chains from the conjugated products. The purity of the final product was determined by UPLC (
The purified IL-15 Analog 21 was coupled to a fatty acid chain with a succinimidyl ester (820044) through the amino group at N-terminal thereof at neutral pH. The reaction was carried out in an IL-15: fatty acid chain ratio of 1:1, wherein the reaction buffer was PBS at pH 7.2. After reacting at room temperature for 1 hour, purification was carried out. Reversed-phase chromatography C8 (Sepax Technologies, Inc.) was used for purification to separate the unconjugated IL-15 and the unreacted fatty acid chains from the conjugated products. The final product was identified by LC-MS. As shown in
The conjugates of IL-15 analogs used in this example were prepared in Example 3.
In this example, biolayer interferomeory (BLI) was used to determine the affinity between the target protein and the receptor. For procedures, see Patricia Estep et al., High throughput solution Based measurement of antibody-antigen affinity and epitope binning, MAbs 2013, 5(2): 270-278. The receptor protein IL15Rα-His used in the experiment was produced by Leto Laboratories Co. Ltd. The formulation of buffer was: 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% Tween 20. The receptor IL15Rα-His was pre-immobilized on a HISIK sensor (Pall Fortebio, Catalog #18-5120), followed by an established process comprising the steps of setting baseline, loading, baseline, association and dissociation. Data acquisition and analysis were carried out using the software Data acquisition 11.0 and Data analysis 11.0 installed with Octet RED96, respectively.
The results for affinity assay of the IL-15 analog and the conjugated products of IL-15 analogs and fatty acid chains to the IL15Rα receptors are shown in Table 6. As compared to the IL-15 analog before conjugation, the affinity of the conjugated products of IL-15 analog and fatty acid chains to the IL15Rα receptor did not change significantly.
The conjugates of IL-15 analogs used in this example were prepared in Example 3.
Eight C57BL/6 mice were divided into 2 groups with 4 mice in each group. Blood was collected from two mice at each time point, and blood was collected cyclically. For one group, the mice were injected with IL-15 at 0.5 mg/kg via tail vein. Blood samples were collected immediately, and then at 10 min, 30 min, 1.5 h and 4 h after administration. For the other group, the mice were injected with long-acting IL-15 at 0.5 mg/kg via tail vein. Blood samples were collected immediately, and then at 1 h, 2 h and 4 h after administration. At each time point, 50 to 100 μL of blood was collected from eye orbit. Then serum was collected for ELISA assay of IL-15.
The calculation formula of half-life is: t1/2=0.693/k, k=(lnc0−lnc)/t. Upon calculation, the half-life of IL-15 was about 5 min, and the half-life of long-acting IL-15 could reach 1.5 h.
The conjugates of IL-15 analogs used in this example were prepared in Example 3.
Fifteen C57BL/6 mice aged 6 to 8 weeks were randomly divided into 3 groups, namely the reagent control group (PBS), the IL-15 group and the long-acting IL-15 group, with 5 mice in each group. On Day 1, the mice were subcutaneously inoculated with B16-F10 cells on the back of the neck, with 2×105/100 μL/mouse. On Days 4 to 8, the PBS group and the IL-15 group were administered intravenously (i.v.) for 5 consecutive days, respectively, at a dose of 20 μg/100 μL/mouse (IL-15 group) or 100 μL/mouse (PBS group). The IL-15 analog conjugate group was administered twice in the same way on Day 4 and Day 7, with the same dosage of 20 μg/100 μL/mouse each time. Tumor sizes were observed from Day 10 and continued for 6 days.
The results are shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019 10910158.5 | Sep 2019 | CN | national |
This application is the national phase entry of International Application No. PCT/CN2020/117279, filed on Sep. 24, 2020, which is based upon and claims priority to Chinese Patent Application No. 201910910158.5, filed on Sep. 25, 2019, the entire contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2020/117279 | 9/24/2020 | WO |
